Adel A Rashad
Overview
Explore the profile of Adel A Rashad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Esquea E, Ciraku L, Young R, Merzy J, Talarico A, Ahmed N, et al.
Front Pharmacol
. 2024 May;
15:1394685.
PMID: 38818373
Breast cancer brain metastasis (BCBM) typically results in an end-stage diagnosis and is hindered by a lack of brain-penetrant drugs. Tumors in the brain rely on the conversion of acetate...
2.
Zhang S, Holmes A, Dick A, Rashad A, Enriquez Rodriguez L, Canziani G, et al.
Retrovirology
. 2021 Oct;
18(1):31.
PMID: 34627310
Background: We previously developed drug-like peptide triazoles (PTs) that target HIV-1 Envelope (Env) gp120, potently inhibit viral entry, and irreversibly inactivate virions. Here, we investigated potential mechanisms of viral escape...
3.
Ang C, Carter E, Haftl A, Zhang S, Rashad A, Kutzler M, et al.
Microorganisms
. 2021 Jul;
9(6).
PMID: 34204725
KR13, a peptide triazole thiol previously established to inhibit HIV-1 infection and cause virus lysis, was evaluated by flow cytometry against JRFL Env-presenting cells to characterize induced Env and membrane...
4.
Kandeil A, Mostafa A, Kutkat O, Moatasim Y, Al-Karmalawy A, Rashad A, et al.
Pathogens
. 2021 Jul;
10(6).
PMID: 34203977
Until now, there has been no direct evidence of the effectiveness of repurposed FDA-approved drugs against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. Although curcumin, hesperidin, and quercetin have...
5.
Jackson M, Cox K, Baugh S, Wakeen L, Rashad A, Lam P, et al.
Cardiovasc Res
. 2021 Jun;
118(7):1771-1784.
PMID: 34132787
Aims: Hydrogen sulfide (H2S) is a potent signalling molecule that activates diverse cardioprotective pathways by post-translational modification (persulfidation) of cysteine residues in upstream protein targets. Heart failure patients with reduced...
6.
Mostafa A, Kandeil A, Elshaier Y, Kutkat O, Moatasim Y, Rashad A, et al.
Pharmaceuticals (Basel)
. 2020 Dec;
13(12).
PMID: 33291642
(1) Background: Drug repositioning is an unconventional drug discovery approach to explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue to alleviate the COVID-19 pandemic...
7.
Ang C, Hossain M, Rajpara M, Bach H, Acharya K, Dick A, et al.
Biochemistry
. 2020 Jan;
59(6):818-828.
PMID: 31942789
Dual-acting virucidal entry inhibitors (DAVEIs) have previously been shown to cause irreversible inactivation of HIV-1 Env-presenting pseudovirus by lytic membrane transformation. This study examined whether this transformation could be generalized...
8.
Meuser M, Rashad A, Ozorowski G, Dick A, Ward A, Cocklin S
Molecules
. 2019 Apr;
24(8).
PMID: 31013646
Small-molecule HIV-1 entry inhibitors are an extremely attractive therapeutic modality. We have previously demonstrated that the entry inhibitor class can be optimized by using computational means to identify and extend...
9.
Aneja R, Grigoletto A, Nangarlia A, Rashad A, Wrenn S, Jacobson J, et al.
J Pept Sci
. 2019 Feb;
25(4):e3155.
PMID: 30809901
Previously, we reported the discovery of macrocyclic peptide triazoles (cPTs) that bind to HIV-1 Env gp120, inhibit virus cell infection with nanomolar potencies, and cause irreversible virion inactivation. Given the...
10.
Xu J, Francis A, Meuser M, Mankowski M, Ptak R, Rashad A, et al.
J Drug Des Res
. 2018 Nov;
5(2).
PMID: 30393786
Recent efforts by both academic and pharmaceutical researchers have focused on the HIV-1 capsid (CA) protein as a new therapeutic target. An interprotomer pocket within the hexamer configuration of the...